Anti-Human CD155/PVR Antibody (7D4)

Catalog No.

FHD09010

Species reactivity

Human

Host species

Mouse

Isotype

IgG1, kappa

Clonality

Monoclonal

Conjugation

Unconjugated

Target

Nectin-like protein 5 receptor, CD155, PVR, PVS, NECL-5

Concentration

1 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

P15151

Applications

FCM

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Clone ID

7D4

CAR-T cells targeting CD155 reduce tumor burden in preclinical models of leukemia and solid tumors., PMID:40478751

NECTIN4 regulates the cell surface expression of CD155 in non-small cell lung cancer cells and induces tumor resistance to PD-1 inhibitors., PMID:40392373

Potential Roles of Serum Exosomal CD155 and its Impact on NK Cell Immunosuppression in Hepatocellular Carcinoma., PMID:40326845

T-cell immunoglobulin and ITIM domain as a target in combo anti-PD-(L)1 cancer therapy., PMID:40294684

Bispecific antibody targeting CD155 mediates T-cell immunotherapy against human gynecological malignancies., PMID:40232354

Targeting the poliovirus receptor to activate T cells and induce myeloid-derived suppressor cells to differentiate to pro-inflammatory macrophages via the IFN-γ-p-STAT1-IRF8 axis in cancer therapy., PMID:40229462

Pinpointing potent hits for cancer immunotherapy targeting the TIGIT/PVR pathway using the XGBoost model, centroid-based virtual screening, and MD simulation., PMID:40194343

TP53 mutations and TET2 deficiency cooperate to drive leukemogenesis and establish an immunosuppressive environment., PMID:40111422

Fc-competent TIGITx4-1BB bispecific antibody exerts potent long-lasting antitumor activity by potentiating CD8+ T cell activity and Fcγ receptor-mediated modulation of the tumor microenvironment., PMID:40010766

Immunomodulation of Pancreatic Cancer via Inhibition of SUMOylation and CD155/TIGIT Pathway., PMID:39975177

Therapeutic drug monitoring and immunogenetic factors associated with the use of adalimumab in Crohn's disease patients., PMID:39959979

Co-blocking TIGIT and PVRIG Using a Novel Bispecific Antibody Enhances Antitumor Immunity., PMID:39851063

Turning Cancer Immunotherapy to the Emerging Immune Checkpoint TIGIT: Will This Break Through the Limitations of the Legacy Approach?, PMID:39771968

[The effect of c-Myc on regulating the immune-related ligands in Y subtype small cell lung cancer through histone deacetylase 1]., PMID:39622733

Targeting the immune privilege of tumor-initiating cells to enhance cancer immunotherapy., PMID:39515328

Myeloid subsets impede the efficacy of anti-PD1 therapy in patients with advanced gastric cancer (WJOG10417GTR study)., PMID:39489543

Prospective Molecular Targets for Natural Killer Cell Immunotherapy against Glioblastoma Multiforme., PMID:39329751

Chitosan/dextran-based organohydrogel delivers EZH2 inhibitor to epigenetically reprogram chemo/immuno-resistance in unresectable metastatic melanoma., PMID:39245506

Glycan-shielded homodimer structure and dynamical features of the canine distemper virus hemagglutinin relevant for viral entry and efficient vaccination., PMID:39046448

Platelet-mediated circulating tumor cell evasion from natural killer cell killing through immune checkpoint CD155-TIGIT., PMID:38779918

A novel anti-LAG-3/TIGIT bispecific antibody exhibits potent anti-tumor efficacy in mouse models as monotherapy or in combination with PD-1 antibody., PMID:38724599

Characterization of a novel anti-PVRIG antibody with Fc-competent function that exerts strong antitumor effects via NK activation in preclinical models., PMID:38554184

TIGIT regulates CD4+ T cell immunity against polymicrobial sepsis., PMID:38545097

TIGIT acts as an immune checkpoint upon inhibition of PD1 signaling in autoimmune diabetes., PMID:38533515

Targeting TIGIT for cancer immunotherapy: recent advances and future directions., PMID:38229100

Synthetic studies on the extracellular domain of the T cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domain (TIGIT) using Trt-K10 solubilizing tags., PMID:38219557

The immune checkpoint TIGIT/CD155 promotes the exhaustion of CD8 + T cells in TNBC through glucose metabolic reprogramming mediated by PI3K/AKT/mTOR signaling., PMID:38216949

Poliovirus receptor inhibition in breast cancer cells induces antitumor immunity via T cell activation., PMID:38187056

Pharmacokinetics (PK) of Tiragolumab in First-in-Human Study in Patients with Mixed Solid Tumors (GO30103)., PMID:38105505

Nectin-4 has emerged as a compelling target for breast cancer., PMID:38059449

A human monoclonal antibody binds within the poliovirus receptor-binding site to neutralize all three serotypes., PMID:37816742

Anti-TIGIT Antibody Tiragolumab Alone or With Atezolizumab in Patients With Advanced Solid Tumors: A Phase 1a/1b Nonrandomized Controlled Trial., PMID:37768658

Biophysical characterization of PVR family interactions and therapeutic antibody recognition to TIGIT., PMID:37675979

CD155 and Its Receptors as Targets for Cancer Therapy., PMID:37629138

Identifying circulating biomarkers for major depressive disorder., PMID:37599893

Diverging prognostic effects of CD155 and CD73 expressions in locally advanced triple-negative breast cancer., PMID:37519808

Combined Blockade of TIGIT and PD-L1 Enhances Anti-Neuroblastoma Efficacy of GD2-Directed Immunotherapy with Dinutuximab Beta., PMID:37444427

TIGIT immune checkpoint blockade enhances immunity of human peripheral blood NK cells against castration-resistant prostate cancer., PMID:37414394

Single-cell RNA sequencing highlights the role of PVR/PVRL2 in the immunosuppressive tumour microenvironment in hepatocellular carcinoma., PMID:37383234

Study on the Effect of EZH2 Inhibitor Combined with TIGIT Monoclonal Antibody against Multiple Myeloma Cells., PMID:37239949

Bispecific anti-CD3×anti-CD155 antibody mediates T-cell immunotherapy in human haematologic malignancies., PMID:37198354

Deficiency of the CD155-CD96 immune checkpoint controls IL-9 production in giant cell arteritis., PMID:37075705

TIGIT mediates activation-induced cell death of ILC2s during chronic airway allergy., PMID:37036426

The IgV domain of the poliovirus receptor alone is immunosuppressive and binds to its receptors with comparable affinity., PMID:36944702

Prognostic impact of PD-L1 and TIGIT expression in non-small cell lung cancer following concurrent chemo-radiotherapy., PMID:36841853

Tissue-Resident Memory T Cells in Pancreatic Ductal Adenocarcinoma Coexpress PD-1 and TIGIT and Functional Inhibition Is Reversible by Dual Antibody Blockade., PMID:36689623

CD155 is a putative therapeutic target in medulloblastoma., PMID:36301489

CD8+ and CD8- NKT Cells Exhibit Phenotypic Changes During Pregnancy., PMID:36102790

Fcγ receptor-mediated cross-linking codefines the immunostimulatory activity of anti-human CD96 antibodies., PMID:35998045

CD155 in tumor progression and targeted therapy., PMID:35870689

Document Download

Anti-Human CD155/PVR Antibody (7D4).pdf